France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with ...

The FDA has approved Dupixent for the treatment of patients aged 12 years and older with CSU who remain symptomatic despite H1 antihistamine treatment.

The FDA has approved the popular drug Dupixent (generic name, dupilumab) for adults and kids 12 and up with chronic spontaneous urticaria (CSU), a long-lasting itchy skin condition, when regular ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

A roundup of health news includes Mexico's first screwworm myiasis case, rising measles cases in Texas, the launch of a new ...

Mexico identifies its first human screwworm myiasis case, Texas battles a significant measles outbreak, Trump's ...

Dupixent approved in the US as the first new targeted therapy ... Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Resubmission of the supplemental biologics license application provided more data on improvement in hives and itching in ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared ...